Kevin Read

Dr. Kevin Read


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2015 in Nature
Verified
Journal Article
Open access
PDF file
BBBeatriz Baragaña
Beatriz Baragaña
IHIrene Hallyburton
Irene Hallyburton
MLMarcus C. S. Lee
Marcus C. S. Lee
NNNeil R. Norcross
Neil R. Norcross
RGRaffaella Grimaldi
Raffaella Grimaldi
IGIan H. Gilbert
Ian H. Gilbert
There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. This discovery of eEF2 as a viable antimalarial drug target opens up new possibilities for drug discovery.

22 August 2022 in Nature Reviews Microbiology
Verified
Journal Article
Open access
PDF file
MRManu De Rycker
Manu De Rycker
SWSusan Wyllie
Susan Wyllie
DHDavid Horn
David Horn
KRKevin Read
Kevin Read
IGIan H. Gilbert
Ian H. Gilbert
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause substantial death and morbidity, particularly in low- and middle-income countries. Although the situation has improved for human African trypanosomiasis, there remains an urgent need for new medicines to treat leishmaniasis and Chagas disease; the clinical development pipeline is particularly sparse for Chagas disease. In this Review, we describe recent advances in our understanding of the biology of the causative pathogens, particularly from the drug discovery perspective, and we explore the progress that has been made in the development of new drug candidates and the identification of promising molecular targets. We also explore the challenges in developing new clinical candidates and discuss potential solutions to overcome such hurdles.

8 April 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SWSusan Wyllie
Susan Wyllie
SBStephen Brand
Stephen Brand
MTMichael Thomas
Michael Thomas
MRManu De Rycker
Manu De Rycker
CCChun-Wa Chung
Chun-Wa Chung
PWPaul G. Wyatt
Paul G. Wyatt
Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and Leishmania infantum , is one of the major parasitic diseases worldwide. There is an urgent need for new drugs to treat VL, because current therapies are unfit for purpose in a resource-poor setting. Here, we describe the development of a preclinical drug candidate, GSK3494245/DDD01305143/compound 8, with potential to treat this neglected tropical disease. The compound series was discovered by repurposing hits from a screen against the related parasite Trypanosoma cruzi . Subsequent optimization of the chemical series resulted in the development of a potent cidal compound with activity against a range of clinically relevant L. donovani and L. infantum isolates. Compound 8 demonstrates promising pharmacokinetic properties and impressive in vivo efficacy in our mouse model of infection comparable with those of the current oral antileishmanial miltefosine. Detailed mode of action studies confirm that this compound acts principally by inhibition of the chymotrypsin-like activity catalyzed by the β5 subunit of the L. donovani proteasome. High-resolution cryo-EM structures of apo and compound 8-bound Leishmania tarentolae 20S proteasome reveal a previously undiscovered inhibitor site that lies between the β4 and β5 proteasome subunits. This induced pocket exploits β4 residues that are divergent between humans and kinetoplastid parasites and is consistent with all of our experimental and mutagenesis data. As a result of these comprehensive studies and due to a favorable developability and safety profile, compound 8 is being advanced toward human clinical trials.

25 July 2018 in Nature
Verified
Journal Article
Closed access
PDF file
SWSusan Wyllie
Susan Wyllie
MTMichael Thomas
Michael Thomas
SPStephen Patterson
Stephen Patterson
SCSabrinia Crouch
Sabrinia Crouch
MRManu De Rycker
Manu De Rycker
IGIan H. Gilbert
Ian H. Gilbert

1 April 2009 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JWJeanette Watson
Jeanette Watson
SWSara Wright
Sara Wright
ALAdam Lucas
Adam Lucas
KCKirsten L. Clarke
Kirsten L. Clarke
JVJean Viggers
Jean Viggers
KRKevin Read
Kevin Read
This study was designed to investigate whether brain unbound concentration (Cu,brain) is a better predictor of dopamine D2 receptor occupancy than total brain concentration, cerebrospinal fluid concentration (CCSF), or blood unbound concentration (Cu,blood). The ex vivo D2 receptor occupancy and concentration-time profiles in cerebrospinal fluid, blood, and brain of six marketed antipsychotic drugs were determined after oral administration in rats at a range of dose levels. The Cu,brain was estimated from the product of total brain concentration and unbound fraction, which was determined using a brain homogenate method. In conclusion, the Cu,brain of selected antipsychotic agents is a good predictor of D2 receptor occupancy in rats. Furthermore, Cu,brain seems to provide a better prediction of D2 receptor occupancy than CCSF or Cu,blood for those compounds whose mechanism of entry into brain tissue is influenced by factors other than simple passive diffusion.

10 September 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BBBeatriz Baragaña
Beatriz Baragaña
NNNeil R. Norcross
Neil R. Norcross
CWCaroline Wilson
Caroline Wilson
APAchim Porzelle
Achim Porzelle
IHIrene Hallyburton
Irene Hallyburton
IGIan H. Gilbert
Ian H. Gilbert
The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC50 = 120 nM) was optimized to lead molecules with low nanomolar in vitro potency. Improvement of the pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency, selectivity, DMPK properties, and efficacy coupled with a novel mechanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498) to preclinical development.